MAPT and Alzheimer disease: In addition to Aβ, plasma tau hyperphosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) can accurately detect PET amyloid and tau pathology, predict future progression to AD dementia, and differentiate AD from non-AD neurodegeneration [19–24].